| Literature DB >> 25957542 |
Kreeta Promthep1, Wichai Eungpinichpong2, Bungorn Sripanidkulchai3, Uraiwan Chatchawan2.
Abstract
BACKGROUND: Physical fitness is a fundamental prerequisite for soccer players. Kaempferia parviflora is an herbal plant that has been used in some Asian athletes with the belief that it might prevent fatigue and improve physical fitness. This study aimed to determine the effects of Kaempferia parviflora on the physical fitness of soccer players.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25957542 PMCID: PMC4538785 DOI: 10.12659/MSMBR.894301
Source DB: PubMed Journal: Med Sci Monit Basic Res ISSN: 2325-4394
Figure 1The 40-yards technical test.
Figure 2Flow of participants in the study.
Demographic data of the participants.
| General characteristics | Treatment (n=30) | Placebo (n=30) | p value |
|---|---|---|---|
| Age (years) | 15.73±0.81 | 15.76±0.94 | 0.884 |
| Systolic blood pressure (mmHg) | 113.20±12.31 | 109.56±10.59 | 0.226 |
| Diastolic blood pressure (mmHg) | 61.40±6.865 | 60.90±4.63 | 0.742 |
| Pulse rate (bpm/min) | 71.16±11.13 | 70.16±7.96 | 0.691 |
| Body mass index (kg/m2) | 20.05±1.84 | 20.37±1.96 | 0.514 |
| Weight (kg) | 58.26±7.33 | 59.60±7.34 | 0.485 |
| Height (cm) | 170.26±6.02 | 170.90±5.74 | 0.678 |
Effect of Kaempferia parviflora on the blood chemistry of the participants.
| Items | Pre-dose baseline score | Post-dose baseline score | P value | Normal value | |
|---|---|---|---|---|---|
| White blood cells (cell/mm3) | Treatment (n=30) | 6920±1246.62 | 7010±1247.43 | 0.608 | 4,000–10,000 |
| Placebo (n=30) | 6770±1343.73 | 7176±957.61 | 0.031 | 4,000–10,000 | |
| Haemoglobin(g/dl) | Treatment (n=30) | 13.61±0.84 | 13.90±0.79 | 0.000 | 13.0–18.0 |
| Placebo (n=30) | 13.47±0.83 | 13.80±0.77 | 0.006 | 13.0–18.0 | |
| Haematocrit(%) | Treatment (n=30) | 40.90±2.56 | 42.26±2.01 | 0.000 | 40–54 |
| Placebo (n=30) | 40.53±2.50 | 42.10±2.00 | 0.000 | 40–54 | |
| Neutrophils(%) | Treatment (n=30) | 57.76±5.73 | 59.40±5.27 | 0.262 | 40–74 |
| Placebo (n=30) | 57.33±8.56 | 58.46±7.05 | 0.442 | 40–74 | |
| Lymphocytes(%) | Treatment (n=30) | 40.13±5.91 | 36.73±5.21 | 0.020 | 19–48 |
| Placebo (n=30) | 40.60±8.09 | 38.23±7.20 | 0.125 | 19–48 | |
| Monocytes(%) | Treatment (n=30) | 0.90±0.84 | 1.66±1.53 | 0.013 | 0–6 |
| Placebo (n=30) | 0.70±0.70 | 1.43±1.27 | 0.007 | 0–6 | |
| Eosinophils(%) | Treatment (n=30) | 1.20±2.24 | 2.20±1.86 | 0.001 | 0–7 |
| Placebo (n=30) | 1.36±2.67 | 1.90±1.56 | 0.164 | 0–7 | |
| Blood urea nitrogen (mg/dl) | Treatment (n=30) | 10.60±0.34 | 12.43±0.36 | 0.000 | 7–21 |
| Placebo (n=30) | 11.63±0.54 | 13.30±0.51 | 0.000 | 7–21 | |
| Creatinine(mg/dl) | Treatment (n=30) | 1.02±0.10 | 0.91±0.92 | 0.000 | 0.7–1.4 |
| Placebo (n=30) | 1.06±0.09 | 0.94±0.09 | 0.000 | 0.7–1.4 | |
| Alkaline phosphatase(U/L) | Treatment (n=30) | 102.93±31.03 | 106.83±32.70 | 0.018 | 26–117 |
| Placebo (n=30) | 98.63 ±28.78 | 105.66±33.83 | 0.000 | 26–117 | |
| Aspartate transaminase(U/L) | Treatment (n=30) | 25.43±4.38 | 25.93±3.75 | 0.378 | 0–38 |
| Placebo (n=30) | 24.96±5.26 | 26.06±4.83 | 0.118 | 0–38 | |
| Alanine transaminase(U/L) | Treatment (n=30) | 15.20 ±5.66 | 14.83±3.94 | 0.604 | 0–40 |
| Placebo (n=30) | 15.03±4.10 | 16.40±5.78 | 0.071 | 0–40 | |
| Sodium (mmol/l) | Treatment (n=30) | 142.36±2.73 | 137.80±1.24 | 0.000 | 135–148 |
| Placebo (n=30) | 142.06±2.57 | 137.46±1.45 | 0.000 | 135–148 | |
| Potassium (mmol/l) | Treatment (n=30) | 4.59±0.30 | 4.36±0.39 | 0.007 | 3.5–5.3 |
| Placebo (n=30) | 4.45±0.31 | 4.24±0.28 | 0.010 | 3.5–5.3 | |
| Chloride (mmol/l) | Treatment (n=30) | 103.53±2.34 | 94.66±16.11 | 0.006 | 98–107 |
| Placebo (n=30) | 103.36±2.29 | 97.23±2.04 | 0.000 | 98–107 | |
| Carbon dioxide (mmol/l) | Treatment (n=30) | 27.30±1.53 | 28.06±1.11 | 0.037 | 22–29 |
| Placebo (n=30) | 27.23±1.04 | 27.7±1.60 | 0.182 | 22–29 | |
Data are presented as the mean ±SD. P and normal values were compared between the pre-dose baseline and post-dose time points,
significant difference compared with the pre-dose baseline and post-dose time point (p<0.05).
The effect of Kaempferia parviflora on the physical fitness of the participants: comparisons between groups.
| Items | Pre-dose baseline score | Post-dose baseline score | |||||
|---|---|---|---|---|---|---|---|
| Week 4 | P-value | Week 8 | P-value | Week 12 | P-value | ||
| Right-hand grip strength (kg/wt) | |||||||
| Treatment (n=30) | 0.65±0.09 | 0.70±0.09 | 0.034 | 0.68±0.10 | 0.024 | 0.65±0.08 | 0.038 |
| Placebo (n=30) | 0.63±0.07 | 0.66±0.07 | 0.63±0.07 | 0.62±0.07 | |||
| Left-hand grip strength (kg/wt) | |||||||
| Treatment (n=30) | 0.62±0.08 | 0.65±0.10 | 0.469 | 0.64±0.08 | 0.024 | 0.61±0.08 | 0.235 |
| Placebo (n=30) | 0.60±0.08 | 0.62±0.07 | 0.59±0.08 | 0.57±0.07 | |||
| Back-and-leg strength (kg/wt) | |||||||
| Treatment (n=30) | 2.77±0.54 | 2.68±0.55 | 0.61 | 2.77±0.55 | 0.377 | 2.79±0.59 | 0.993 |
| Placebo (n=30) | 2.45±0.39 | 2.45±0.51 | 2.44±0.40 | 2.53±0.52 | |||
| Sit-and-reach test (cm) | |||||||
| Treatment (n=30) | 17.98±4.60 | 16.43±5.15 | 0.926 | 16.88±5.19 | 0.452 | 18.28±5.10 | 0.729 |
| Placebo (n=30) | 16.14±4.93 | 14.64±4.92 | 14.61±5.24 | 17.01±4.55 | |||
| 40-yard technical test (s) | |||||||
| Treatment (n=30) | 11.61±0.70 | 12.06±1.16 | 0.746 | 11.50±0.74 | 0.458 | 10.08±0.47 | 0.078 |
| Placebo (n=30) | 11.99±0.86 | 12.34±1.33 | 11.46±0.75 | 10.47±0.90 | |||
| 50-metre sprint (s) | |||||||
| Treatment (n=30) | 6.24±0.31 | 6.26±0.31 | 0.752 | 6.37±0.26 | 0.255 | 6.33±0.24 | 0.204 |
| Placebo (n=30) | 6.29±0.37 | 6.33±0.49 | 6.50±0.50 | 6.47±0.52 | |||
| VO2max (ml/kg/min) | |||||||
| Treatment (n=30) | 45.09±9.88 | 46.95±7.61 | 0.657 | 49.40±8.40 | 0.578 | 51.05±8.40 | 0.053 |
| Placebo (n=30) | 45.09±9.96 | 47.85±10.08 | 48.34±7.17 | 47.10±8.45 | |||
The effects of Kaempferia parviflora on physical fitness. P-values are presented as the mean±SD.
Significant difference from the placebo group in the same week (p<0.05).
The effects of Kaempferia parviflora on the physical fitness of the participants: comparisons between the pre- and post-dose baseline scores.
| Item | Pre-dose baseline score | Post-dose baseline score | Within group | |||
|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | F-test | P-value | ||
| Right-hand grip strength (kg/wt) | ||||||
| Treatment (n=30) | 0.65±0.09 | 0.70±0.09* | 0.68±0.10 | 0.65±0.08 | 9.373 | <0.001 |
| Placebo (n=30) | 0.63±0.07 | 0.66±0.07* | 0.63±0.07 | 0.62±0.07 | 9.345 | <0.001 |
| Left-hand grip strength (kg/wt) | ||||||
| Treatment (n=30) | 0.62±0.08 | 0.65±0.10 | 0.64±0.08 | 0.61±0.08 | 3.195 | 0.039 |
| Placebo (n=30) | 0.60±0.08 | 0.62±0.07 | 0.59±0.08 | 0.57±0.07 | 6.617 | 0.001 |
| Back-and-leg strength (kg/wt) | ||||||
| Treatment (n=30) | 2.77±0.54 | 2.68±0.55 | 2.77±0.55 | 2.79±0.59 | 0.968 | 0.404 |
| Placebo (n=30) | 2.45±0.39 | 2.45±0.51 | 2.44±0.40 | 2.53±0.52 | 0.771 | 0.475 |
| Sit-and-reach test (cm) | ||||||
| Treatment (n=30) | 17.98±4.60 | 16.43±5.15* | 16.88±5.19 | 18.28±5.10 | 6.212 | 0.002 |
| Placebo (n=30) | 16.14±4.93 | 14.64±4.92* | 14.61±5.24* | 17.01±4.55 | 12.449 | <0.001 |
| 40-yard technical test (s) | ||||||
| Treatment (n=30) | 11.61±0.70 | 12.06±1.16 | 11.50±0.74 | 10.08±0.47* | 42.964 | <0.001 |
| Placebo (n=30) | 11.99±0.86 | 12.34±1.33 | 11.46±0.75* | 10.47±0.90* | 28.789 | <0.001 |
| 50-metre sprint (s) | ||||||
| Treatment (n=30) | 6.24±0.31 | 6.26±0.31 | 6.37±0.26* | 6.33±0.24 | 3.548 | 0.021 |
| Placebo (n=30) | 6.29±0.37 | 6.33±0.49 | 6.50±0.50* | 6.47±0.52* | 5.101 | 0.004 |
| VO2max (ml/kg/min) | ||||||
| Treatment (n=30) | 45.09±9.88 | 46.95±7.61 | 49.40±8.40 | 51.05±8.40* | 4.111 | 0.012 |
| Placebo (n=30) | 45.09±9.96 | 47.85±10.08 | 48.34±7.17 | 47.10±8.45 | 1.62 | 0.201 |
Effect of Kaempferia parviflora on physical fitness. P values are presented as the mean ±SD. ** significant difference compared with the pre-dose baseline score (p<0.05).